Viewing Company Abbott Labs | StockChase
stockchase picture

Compiling comments that experts make about stocks while on public TV.

Abbott Labs Stock Symbol: ABT-N

Last Price Recorded: $44.7100 on 2017-05-26

Globe 5 day average
Google Discussions (view only)
yahoo discussion
Bloomberg
Date Signal Expert Opinion Price
2008-11-21 TOP PICK Walter Gerasimowicz Diagnostic equipment stents and some new blockbuster drugs. Drug industry and healthcare services might come under some pressure with the new administration, which is the risk they may face.
Price:
$51.520
Subject:
US & GLOBAL LARGE CAP
Bias:
UNKNOWN
Owned:
Yes
2013-09-19 TOP PICK Stuart Hinshelwood

Diversified healthcare company. Recently spun off their pharmaceutical business. Has some decent growth over the next couple of years. Thinks it can get to $42 over a 12-18 time period.


Price:
$35.340
Subject:
US EQUITIES
Bias:
CAUTIOUS
Owned:
Yes
2013-11-01 TOP PICK Stuart Hinshelwood

Bought this because he was looking to increase his exposure to healthcare. Not that expensive. Nice diverse portfolio. Good exposure, both in North America and outside. Could be $42 over 12 months.


Price:
$36.960
Subject:
US EQUITIES
Bias:
BULLISH
Owned:
Yes
2014-02-18 BUY Stuart Hinshelwood

Growth in large-cap pharmaceutical business is fairly anaemic. There are not a lot of great growth prospects. What he does like about this company is that they have a medical technology business, a nutritionals business as well as a traditional pharmaceutical business i.e. all the components of the healthcare sector. Feels there is some growth from an earnings perspective. (See Top Picks.)


Price:
$38.930
Subject:
US EQUITIES
Bias:
CAUTIOUS
Owned:
Yes
2011-10-19 HOLD Stan Wong The market likes the split. Going to split into pharma and medical space. 3.6% dividend. Hold on to it for the time being.
Price:
$53.250
Subject:
NORTH AMERICAN - LARGE & ETFs
Bias:
DEFENSIVE
Owned:
No
2012-04-19 BUY Stan Wong This is a more of a growth company in the healthcare space. You are looking at higher single-digit growth and you are getting it for around 11-12 times PE. Nice dividend at around 3.4%.
Price:
$59.510
Subject:
NORTH AMERICAN - LARGE & ETFs
Bias:
CAUTIOUS
Owned:
No
2014-04-09 DON'T BUY Stan Wong

This one has outperformed the health care sector over the last few years.  Sees a 15% growth rate on the dividend, but it is low compared to others.  Prefers PFE-N.


Price:
$37.630
Subject:
NORTH AMERICAN - LARGE & ETFs
Bias:
SELECTIVE
Owned:
No
2015-09-17 COMMENT Stan Wong

In the healthcare space, he prefers focusing on the health benefit managers such as an Aetna or United Health Group or some names in the biotech space such as Gilead, etc. The valuation on this one looks decent at 20X forward earnings and the growth rate is about 12%. The stock has dropped off quite a bit, so it is not in the space that he likes. (See Top Picks.)


Price:
$44.240
Subject:
NORTH AMERICAN - LARGE & ETFs
Bias:
UNKNOWN
Owned:
No
2015-04-27 BUY on WEAKNESS Peter Brieger

He would wait for some sort of correction. Likes this. It is a leader in its field.


Price:
$47.490
Subject:
NORTH AMERICAN - LARGE
Bias:
BULLISH
Owned:
Yes
2016-06-22 COMMENT Paul Macdonald

Has 4 businesses, an established pharma, labs division, diagnostic division and a medical device division. Has owned this for some time. Recently made a couple of acquisitions, so the valuation hasn’t kept up with its peers. Part of the reason is because of hair on some of the acquisitions. They are looking to acquire another company for about $5 billion + $3 billion in debt, which would be complementary to their monitoring devices. Their larger acquisition is St. Jude Medical, highly complementary and a leader in cardiac rhythmic management. Paid $25 billion with about $5 billion debt. This is going to be cash and stock. A situation where patience is required. You have 6 months of a bit of noise around the acquisitions, and after that they will be integrated and begin their growth. He is writing options on this.


Price:
$38.740
Subject:
HEALTHCARE
Bias:
UNKNOWN
Owned:
Yes
2017-02-22 COMMENT Paul Macdonald

This is sitting at around 17.5X forward earnings. The St. Jude acquisition was a big one for them. It expanded their balance sheet. They still have the Alere acquisition overhang. Have some things to chew through this year in order to get the multiple expansion up to something like 21X, where its direct competitors would trade at. If a longer-term holder, you do have some upside on this.


Price:
$45.010
Subject:
HEALTHCARE
Bias:
BULLISH on HEALTH CARE
Owned:
Unknown
2017-05-10 COMMENT Paul Macdonald

Had owned this in the past. They made a number of acquisitions, so patience is required. Acquired St. Jude, which he had seen losing market share to Boston Scientific. One concern is that they bloated out their balance sheet for this acquisition. Trading at about 18X, so not terribly inexpensive. Also, there are still some balance sheet risk. If you are a long-term player, they have a proven ability to execute on their operations, and it will likely get re-rated.


Price:
$44.500
Subject:
HEALTHCARE
Bias:
UNKNOWN
Owned:
No
2013-03-07 BUY Patrick Horan

Just initiated 3.6% dividend.  Does like it.  They may put growth back into business model or you have an activist shareholder that puts them up for sale.  If stock stays flat you will collect the divided.


Price:
$34.430
Subject:
NORTH AMERICAN
Bias:
BULL
Owned:
Yes
2007-08-29 BUY Norman Levine In the healthcare area this is an attractive name. Have medical devices, nutrition products and pharmaceuticals. Had troubles a few years ago but has gotten its act together.
Price:
$51.490
Subject:
NORTH AMERICAN - LARGE
Bias:
DEFENSIVE
Owned:
Unknown
2011-10-24 COMMENT Norman Levine Likes health care companies generally because they’re defensive. Splitting their drug company from the rest of the company. Likes this as you get pure plays.
Price:
$53.450
Subject:
NORTH AMERICAN - LARGE
Bias:
CAUTIOUS
Owned:
No
Showing 1 to 15 of 104 entries
<< < 1 2 3 4 5 > >>

No Comments.


You must be logged in to comment.